Theravance, Inc. (NASDAQ: THRX) announced today that it has enrolled the last patient in its first Phase 3 clinical program with the investigational antibiotic telavancin in patients with complicated skin and skin structure infections (cSSSI) due to Gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).
